{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:32:56Z","timestamp":1788474776923,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcf.2024.04.010","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:44:45Z","timestamp":1714571085000},"page":"1080-1086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment \u2013 A Danish prospective cohort"],"prefix":"10.1016","volume":"23","author":[{"given":"Lue Katrine Drasb\u00e6k","family":"Philipsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-210X","authenticated-orcid":false,"given":"Hanne Vebert","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne Hastrup","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-6403","authenticated-orcid":false,"given":"Mette Frahm","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-0155","authenticated-orcid":false,"given":"Daniel","family":"Faurholt-Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-3893","authenticated-orcid":false,"given":"Frederik","family":"Buchvald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Gjerum","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2024.04.010_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.04.010_bib0002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"2023","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"169","key":"10.1016\/j.jcf.2024.04.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0029-2023","article-title":"Guidance and standard operating procedures for functional exercise testing in cystic fibrosis","volume":"32","author":"Saynor","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.010_bib0004","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000439057","article-title":"Statement on exercise testing in cystic fibrosis","volume":"90","author":"Hebestreit","year":"2015","journal-title":"Respiration"},{"issue":"8","key":"10.1016\/j.jcf.2024.04.010_bib0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1164\/rccm.201806-1110OC","article-title":"Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis","volume":"199","author":"Hebestreit","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcf.2024.04.010_bib0006","article-title":"Health-Related Quality of Life in Adults with Cystic Fibrosis: familial, Occupational, Social, and Mental Health Predictors","volume":"10","author":"Ancel","year":"2022","journal-title":"Healthc (Basel)"},{"key":"10.1016\/j.jcf.2024.04.010_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2466-14-26","article-title":"Quality of life is associated with physical activity and fitness in cystic fibrosis","volume":"14","author":"Hebestreit","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.010_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4187\/respcare.06185","article-title":"Peak oxygen uptake and mortality in cystic fibrosis: systematic review and meta-analysis","volume":"64","author":"Vendrusculo","year":"2019","journal-title":"Respir Care"},{"issue":"10212","key":"10.1016\/j.jcf.2024.04.010_bib0009","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2024.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.04.010_bib0011","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1513\/AnnalsATS.202304-317OC","article-title":"Cardiopulmonary exercise testing provides prognostic information in advanced cystic fibrosis lung disease","volume":"21","author":"Radtke","year":"2024","journal-title":"Ann Am Thorac Soc."},{"issue":"2","key":"10.1016\/j.jcf.2024.04.010_bib0012","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2021.11.011","article-title":"Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies","volume":"21","author":"Caterini","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2024.04.010_bib0013","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1002\/ppul.25059","article-title":"Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor\/ivacaftor treatment","volume":"55","author":"Ejiofor","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.010_bib0014","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcf.2022.05.009","article-title":"Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor\/Ivacaftor and Tezacaftor\/Ivacaftor","volume":"21","author":"Rysgaard","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.04.010_bib0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcf.2019.03.001","article-title":"Effects of Lumacaftor\/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis","volume":"18","author":"Savi","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.04.010_bib0016","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2020.12.006","article-title":"VO(2max) as an exercise tolerance endpoint in people with cystic fibrosis: lessons from a lumacaftor\/ivacaftor trial","volume":"20","author":"Wilson","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis","author":"Causer","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.010_bib0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1164\/rccm.167.2.211","article-title":"ATS\/ACCP statement on cardiopulmonary exercise testing","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.04.010_bib0019","unstructured":"Hansen JE, Sue DY, Stringer WW, Whipp BJ, Wasserman K. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. 4. \/Karlman Wasserman, James E. Hansen, Darryl Y. Sue, William W. Stringer, Brian J. Whipp. editor Philadelphia: Lippincott Williams & Wilkins; 2005."},{"issue":"3","key":"10.1016\/j.jcf.2024.04.010_bib0020","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1183\/20734735.012717","article-title":"The Global Lung Function Initiative (GLI) Network: bringing the world's respiratory reference values together","volume":"13","author":"Cooper","year":"2017","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.jcf.2024.04.010_bib0021","first-page":"274","article-title":"Exercise testing to evaluate therapeutic interventions in chronic respiratory diseases","volume":"4","author":"Puente-Maestu","year":"2018","journal-title":"Barcelona Respir Netw Rev"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.010_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.010_bib0023","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fphys.2019.01382","article-title":"Exercise physiology across the lifespan in cystic fibrosis","volume":"10","author":"Shei","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jcf.2024.04.010_bib0024","series-title":"eaC-MoELiCFALUoIM. diet and exercise in cystic fibrosis","author":"Hulzebos","year":"2015"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.010_bib0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/17476348.2014.966693","article-title":"Cystic fibrosis and physiological responses to exercise","volume":"8","author":"Williams","year":"2014","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.010_bib0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0954-6111(97)90135-9","article-title":"Relationship between dyspnoea, pulmonary function and exercise capacity in patients with cystic fibrosis","volume":"91","author":"de Jong","year":"1997","journal-title":"Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T19:26:33Z","timestamp":1733253993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1569199324000559"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.04.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment \u2013 A Danish prospective cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}